Alkermes Plc
ALKS
View Detailed Chart
28.520USD
+0.030+0.11%
Close 12/24, 16:00（ET）Quotes delayed by 15 min
4.71BMarket Cap
13.82P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+0.11%
5 Days
+2.55%
1 Month
-1.62%
6 Months
-1.31%
Year to Date
-0.83%
1 Year
-3.81%
View Detailed Chart
TradingKey Stock Score of Alkermes Plc
Currency: USD Updated: 2025-12-24Key Insights
Alkermes Plc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 16/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 43.88.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Alkermes Plc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
17
analysts
Buy
Current Rating
43.875
Target Price
+49.18%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Alkermes Plc Highlights
StrengthsRisks
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 40.10% year-on-year.
Fairly Valued
The company’s latest PE is 13.82, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 175.23M shares, decreasing 0.01% quarter-over-quarter.
Held by Chuck Royce
Star Investor Chuck Royce holds 49.77K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.31.
Alkermes Plc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Alkermes Plc Info
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
Ticker SymbolALKS
CompanyAlkermes Plc
CEOPops (Richard F)
Websitehttps://www.alkermes.com/
FAQs
What is the current price of Alkermes Plc (ALKS)?
The current price of Alkermes Plc (ALKS) is 28.520.
What is the symbol of Alkermes Plc?
The ticker symbol of Alkermes Plc is ALKS.
What is the 52-week high of Alkermes Plc?
The 52-week high of Alkermes Plc is 36.450.
What is the 52-week low of Alkermes Plc?
The 52-week low of Alkermes Plc is 25.165.
What is the market capitalization of Alkermes Plc?
The market capitalization of Alkermes Plc is 4.71B.
What is the net income of Alkermes Plc?
The net income of Alkermes Plc is 367.07M.
Is Alkermes Plc (ALKS) currently rated as Buy, Hold, or Sell?
According to analysts, Alkermes Plc (ALKS) has an overall rating of Buy, with a price target of 43.875.
What is the Earnings Per Share (EPS TTM) of Alkermes Plc (ALKS)?
The Earnings Per Share (EPS TTM) of Alkermes Plc (ALKS) is 2.064.
Related Instruments
+0.41%
+0.94%
+0.51%
+0.34%
-0.17%
+1.42%
+0.75%
+1.80%
+0.38%
+0.66%
+0.08%
+0.82%
+0.81%
+0.08%
+0.23%
-0.05%
-0.19%
0.00%
+1.54%
+0.50%Popular Symbols
